Law360, New York (October 05, 2012, 5:19 PM ET) -- Health maintenance organization operator Kaiser Foundation Health Plan Inc. asked the First Circuit on Thursday to uphold a $142 million jury award against Pfizer Inc. in multidistrict litigation over misbranding of pain drug Neurontin, saying Pfizer’s own fraud had prevented it from introducing new evidence of the drug’s alleged effectiveness.
According to Kaiser’s brief, U.S. District Judge Patti B. Saris correctly denied Pfizer a new trial over its claims that it was unfairly denied a motion to admit a new article by health care research group...
HMO Asks 1st Circ. To Uphold $142M Neurontin Verdict
To view the full article, take a free trial now.
